Sermonix Pharmaceuticals and Regor Therapeutics Group have entered into a collaboration to identify new drug targets and therapeutics in breast oncology.
The agreement is expected to integrate Sermonix’s expertise in clinical drug development with Regor’s computational drug discovery capabilities to support advancements in treatments for metastatic breast cancer.
Sermonix, a privately held biopharmaceutical company, is developing oral lasofoxifene, a Phase 3 candidate for ESR1-mutated ER+/HER2- metastatic breast cancer.
The company’s focus includes drug development, commercialisation strategies, and market positioning for new therapies.
The collaboration will also explore treatment areas related to onco-sexuality, cardio-oncology, and bone health, which have been identified as emerging concerns among patients with breast cancer.
Regor, a clinical-stage biopharmaceutical company, will contribute its rCARD platform, which applies computational methods to drug discovery and development. rCARD expands to Regor Computer Accelerated Rational Discovery.
The platform integrates target identification, molecular design, translational research, and clinical development to streamline the drug development process. The collaboration aims to leverage this technology to accelerate the identification of potential breast cancer treatments.
Regor founder and CEO Xiayang Qiu said: “After engaging in extensive discussions with Sermonix, closely watching its clinical and commercial market development efforts in the breast oncology segment, it is obvious the company shares the vision and dedication of our team at Regor.
“The Sermonix team demonstrates both expertise and passion, and we are truly excited to embrace that as part of our work in identifying optimal drug candidates that can make a significant impact for patients with metastatic breast cancer.”
Sermonix is currently enrolling participants for its ELAINE-3 study, which is evaluating the combination of lasofoxifene with the CDK 4/6 inhibitor abemaciclib compared to fulvestrant plus abemaciclib in patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation.
Sermonix founder and CEO David Portman said: “Regor’s translational to clinical approach – and then confirmation of clinical impact – is one we greatly admire and is producing molecules for development that will be best in class from both an efficacy and tolerability perspective.
“At Sermonix, we believe patients deserve not only highly efficacious treatments, but also ones that are well tolerated and potentially improve quality of life for breast cancer patients.
“Deep patient insights and the potential to develop targets that can ultimately provide efficacy while addressing areas of key concerns to patients such as vaginal, bone, and cardiovascular health would be fulfilling on the promise of optimised drug development.”
